FDA Reviews Novo Nordisk's Weekly Insulin Amid Safety Concerns
TL;DR Summary
FDA advisers are divided on the approval of Novo Nordisk's once-weekly insulin icodec for type 1 diabetes, citing concerns over higher hypoglycemia risks compared to daily insulin degludec. The FDA will consider the committee's input but is not bound by it.
- FDA advisers weigh benefits of weekly insulin for people with diabetes CNN
- FDA advisory committee reviews Novo Nordisk insulin icodec for T1D Yahoo Finance
- Safety risk cited for Novo Nordisk's long-acting insulin Axios
- Novo's Insulin Icodec: Hypoglycemia Events In Type 1 Diabetics Put Broad Indication At Risk Pink Sheet
- US FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin Reuters
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
3 min
vs 4 min read
Condensed
94%
686 → 41 words
Want the full story? Read the original article
Read on CNN